Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Thromboembolic complications can occur with recombinant activated factor VII (rFVIIa) treatment in trauma and surgical patients but they are infrequent in hemophiliacs. Bleeding diathesis in these conditions is often attributed to reduced thrombin generation, which may be improved with rFVIIa. Normally, thrombin that diffuses from local vascular injury sites is quickly inactivated by antithrombin (AT). Evaluating the influence of AT levels on thrombin generation in hypocoagulable FVIII-deficient plasma would be a simple approach to better understand how procoagulant stimuli, such as rFVIIa, might result in postoperative thrombotic complications. We hypothesize that reduced AT concentrations would increase the procoagulant effects of rFVIIa in FVIII-deficient plasma.

Methods: Thrombin generation was evaluated in vitro in FVIII-deficient and AT/FVIII-deficient plasma using thrombelastography and a thrombin generation assay (Thrombinoscope). The effect of added rFVIIa on these variables was evaluated.

Results: Delayed thrombus formation based on thrombelastography in FVIII-deficient plasma was predictably reversed by rFVIIa. Improved thrombus formation and responses to rFVIIa were observed when AT levels were 20%-50% of normal. Thrombin generation in FVIII-deficient plasma increased in an inverse relationship to AT levels. Supplemental rFVIIa decreased the lag time of thrombin generation but not the amount of thrombin generated.

Conclusions: Using FVIII-deficient plasma as a model of reduced thrombin generation, we demonstrate that low AT levels enhance in vitro hemostatic responses to rFVIIa. Reduced AT levels in trauma and surgical patients with normal or increased FVIII levels may be considered potentially prothrombotic. Monitoring of AT levels during rFVIIa therapy may thus reduce thrombotic complications in nonhemophiliacs.

Download full-text PDF

Source
http://dx.doi.org/10.1213/ane.0b013e3181618702DOI Listing

Publication Analysis

Top Keywords

thrombin generation
28
fviii-deficient plasma
16
rfviia
10
thrombin
9
recombinant activated
8
activated factor
8
factor vii
8
trauma surgical
8
surgical patients
8
reduced thrombin
8

Similar Publications

3-O-sulfation of heparan sulfate (HS) is the key determinant for binding and activation of Antithrombin III (AT). This interaction is the basis of heparin treatment to prevent thrombotic events and excess coagulation. Antithrombin-binding HS (HSAT) is expressed in human tissues, but is thought to be expressed in the subendothelial space, mast cells, and follicular fluid.

View Article and Find Full Text PDF

Objective: To study the application of thrombolysis diagram (TEG) and routine coagulation test in the evaluation of coagulation function in patients with hepatic hydatid.

Methods: The observation group consisted of 69 cases of hydatid liver patients undergoing elective combined segmenectomy, and the control group consisted of 69 healthy subjects. The correlation analysis of TEG, six coagulation items and PLT in the preoperative observation group and control group was conducted.

View Article and Find Full Text PDF

Background: Combined oral contraceptives (COCs) are associated with an increased risk of venous thromboembolism. Several changes are induced in both coagulant and anticoagulant factors, of which the impact on protein S (PS) and tissue factor pathway inhibitor (TFPI) may be especially important. The global thrombin generation (TG) assay, which accounts for all pro- and anticoagulant factors, can be used to evaluate the effect of the changes of PS and TFPI using antibodies to eliminate the effect of these inhibitors.

View Article and Find Full Text PDF

Background: Inherited thrombophilia (IT) is a genetically determined predisposition to thromboembolic events. Beyond the well-known G20210A mutation, there has been limited research on other prothrombin mutations in the Chinese population.

Objectives: This study aimed to identify and characterize a novel prothrombin mutation in a Han Chinese family with IT.

View Article and Find Full Text PDF

Coagulation factor XII has been identified as a potential drug target that could prevent thrombosis without increasing the risk of bleeding. However, human data to support the development of factor XII-directed therapeutics are lacking. To assess the role of factor XII in venous thromboembolism, we examine genetic variation in the coding region of the F12 locus across 703,745 participants in the UK Biobank and NIH All of Us biorepositories.

View Article and Find Full Text PDF